4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Diffuse Large B-Cell Lymphoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2155 ongoing clinical trials involving Diffuse Large B-Cell Lymphoma
Of the 2155 trials,559 trials are in Phase I/II
Furthermore, 519 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Diffuse Large B-Cell Lymphoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Diffuse Large B-Cell Lymphoma , an Oncology indication. The largest number of ongoing clinical trials for Diffuse Large B-Cell Lymphoma is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Diffuse Large B-Cell Lymphoma-related drug trials.

National Cancer Institute US: The leading ongoing Diffuse Large B-Cell Lymphoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Diffuse Large B-Cell Lymphoma -related ongoing clinical trials.

F. Hoffmann-La Roche Ltd, Memorial Sloan Kettering Cancer Center,Ruijin Hospital, and University of Texas MD Anderson Cancer Center are a few other notable clinical trial sponsors involving Diffuse Large B-Cell Lymphoma . A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Diffuse Large B-Cell Lymphoma

Pembrolizumab (Keytruda), Rituximab (MabThera, Rituxan, Ristova), and Rituximab biosimilar (Truxima/Blitzima/Tuxella/Ritemvia/Rituzena) are among the key marketed drugs involving Diffuse Large B-Cell Lymphoma .

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonistmechanism of action. It is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab (Keytruda)was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including Merck Sharp & Dohme Corp.

Rituximab (MabThera, Rituxan, Ristova) is an anti-neoplastic agent. It functions via Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) mechanism of action.  It is formulated as an injectable concentrate for solution for intravenous route and solution for subcutaneous route of administration.Rituximab was first approved in 1997 and is marketed globally including the US, the UK, France, Germany, and Japan by several prominent pharma giants including Genentech USA Inc.